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Purpose: This study applies treatment methods to rat retinas subjected to acute ischemia reperfusion injury and compares
the efficacy of memantine, hyperbaric oxygen (HBO) therapy, and brimonidine by histopathological examination.
Methods: Thirty adult Wistar albino rats were divided into five groups after retinal ischemia was induced by elevating
the intraocular pressure to 120 mmHg. The groups were as follows: group 1: control; group 2: acute retinal ischemia (ARI)
model but without treatment group; group 3: memantine (MEM) treatment group; group 4: HBO therapy group; and group
5: brimonidine treatment (BRI) group. In the control group, right eyes were cannulated with a 30-gauge needle and removed
without causing any intraocular pressure change. The ARI group was an acute retinal ischemia model, but without
treatment. In the MEM group, animals were given a unique dose of intravenous 25 mg/kg memantine by the tail vein route
after inducing ARI. In the HBO group, at 2 h following ARI, HBO treatment was applied for nine days. In the BRI group,
a 0.15% brimonidine tartrate eye drop treatment was applied twice a day (BID) for seven days before ARI. Twenty-one
days after establishing ischemia reperfusion, the right eyes were enucleated after the cardiac gluteraldehyde perfusion
method, and then submitted to histological evaluation.
Results: On average, the total retinal ganglion cell number was 239.93±8.60 in the control group, 125.14±7.18 in the ARI
group, 215.89±8.36 in the MEM group, 208.69±2.05 in the HBO group, and 172.27±8.16 in the BRI group. Mean apoptotic
indexes in the groups were 1.1±0.35%, 57.71±0.58%, 23.57±1.73%, 15.63±0.58%, and 29.37±2.55%, respectively.
Conclusions: The present study shows that memantine, HBO, and brimonidine therapies were effective in reducing the
damage induced by acute ischemia reperfusion in the rat retina. Our study suggests that these treatments had beneficial
effects due to neuroprotection, and therefore may be applied in clinical practice.
Central retinal artery occlusion (CRAO) causes severe
loss of vision. Treatment trials include massaging of the globe,
paracentesis, antiglaucomatous eye drops, and hemodilution
or lysis therapy, which in individual cases can improve the
visual outcome, although in general the prognosis remains
poor.
Acute  retinal  ischemia  (ARI)  is  a  vision-threatening
condition  encountered  in  several  pathologies,  including
central and branch retinal artery occlusion, anterior ischemic
optic neuropathy, venous occlusive disorders, ocular trauma,
and acute angle closure glaucoma [1].
Reperfusion  after  initial  ischemia  paradoxically
maintains the destruction process, perhaps due to increased
levels  of  extracellular  neurotransmitters,  reactive  oxygen
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species, and waste products damaging previously unharmed
cells during reoxidization [1,2].
Central retinal artery occlusion is a typical example of
ARI. Classical and complex treatments have not yet yielded
the expected success. Hyperbaric oxygen (HBO) therapy was
successfully used in the treatment of central retinal artery
occlusion [3,4] and branch retinal artery occlusion, including
Susac’s syndrome [5,6]. HBO therapy was reported to be
useful  in  the  treatment  of  ocular  vascular  diseases  [7,8].
Vasoconstriction or vascular occlusion of the retinal vessels
is probably a direct response to the interaction between free
oxygen  radicals  and  nitric  oxide,  together  with  the
autoregulation  that  occurs  in  this  treatment.  During  HBO
therapy, oxygen saturation rises up to 23% and the retina is
not damaged [9]. However, the acclaimed HBO therapy has
the  drawback  that  it  must  be  applied  shortly  after  the
occurrence of the ischemia to be effective. A phase called
“ischemic penumbra,” characterized by its reversibility, was
described  as  occurring  before  definitive  ischemic  damage
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1024[10].  The  duration  of  this  critical  period  is  impossible  to
determine in humans. It is generally admitted that an accurate
and rapid therapy must be applied within 24 h. Therefore,
practical and urgent therapy is needed, and determining which
treatment can provide this was the goal of our study [11-14].
During ischemia, there is activation of the extracellular
glutamate-bound  N-methyl-D-aspartic  acid  (NMDA)
receptors, which provokes apoptosis by means of intracellular
calcium  accumulation  [15,16].  Memantine,  known  as  a
glutamatergic NMDA receptor antagonist, is a derivative of
amantadine  that  inhibits  excitotoxicity  and  neuronal  cell
death. The protective effect of memantine on retinal ganglion
cells (RGCs) has been explained by the presence of NMDA
receptors in these cells [17]. Memantine has been used in the
treatment of many clinical conditions, including influenza,
Parkinson  disease  and  spasticity,  Alzheimer  disease,  and
vascular  dementia  [18].  The  neuroprotective  properties  of
memantine have been studied by several laboratories in a large
number of in vitro and in vivo animal models, such as in the
case of brain stroke, glaucoma, and retinal ischemia–related
conditions [19].
Alpha-2a adrenergic receptor agonists are thought to be
neuroprotective,  preventing  RGC  death  independent  of
pressure reduction. In vivo studies have shown that in addition
to lowering intraocular pressure, alpha-2a adrenergic agonists
such  as  brimonidine  decrease  RGC  death  subsequent  to
increases in intraocular pressure, retinal ischemia, or optic
nerve crush. Alpha-2 receptor activation has been implicated
in  enhanced  neuronal  survival  in  glaucomatous  in  vivo
models, and hence alpha-2 agonists are some of the most
studied neuroprotective agents [20-23].
The  aim  of  our  research  was  to  apply  the  methods
mentioned above to rat retinas subjected to acute ischemia
reperfusion injury and to compare the efficacy of memantine,
HBO  therapy,  and  brimonidine  by  histopathological
examination.
METHODS
Subjects: Thirty adult Wistar albino rats at the same age of 24
weeks were used. The rats were housed in the Laboratory of
Marmara University Experimental Animal Laboratory under
a  constant  light-dark  cycle  and  were  fed  ad  libitum  with
normal rat chow and given free access to water. All efforts
were made to minimize pain and distress. Protocols were
approved by the Şişli Etfal Education and Research Hospital
Ethical Animal Care Committee (Permission no. 52/2007).
Acute  retinal  ischemia  model:  Rats  were  anesthetized
intraperitoneally with ketamine hydrochloride (100 mg/kg)
and chlorpromazine (25 mg/kg). Pupils were dilated with a
topical application of tropicamide 1% (Tropamid; Visufarma,
Milan,  Italy).  Local  anesthesia  was  obtained  using
proparacaine 0.5% (Alcaine; Alcon Labs., Ft. Worth, TX).
The anterior chamber of the right eyes were cannulated with
a 30-gauge needle attached to a raised saline reservoir. Retinal
ischemia was induced by elevating the intraocular pressure to
120  mmHg.  Measurement  of  intraocular  pressure  was
conducted  using  a  TonoPen  XL  tonometer  (Mentor,  Inc.,
Norwell,  MA)  calibrated  according  to  the  manufacturer’s
instructions.
A hand-held ophthalmoscope was used to visually inspect
the retinal blood vessels and verify ischemia. After 60 min,
the saline reservoir was lowered and the intraocular pressure
and retinal circulation were allowed to return to normal over
a period of 10 min. The cannula was then removed from the
cornea and the animals were allowed to recover.
Hyperbaric  oxygen  therapy:  For  HBO  therapy,  rats  were
placed in a small cylindrical monoplace research chamber of
0.6 m3. The chamber was flushed with 100% oxygen for 10
min to vent the air inside before the compression. The HBO
therapy session consisted of 100% oxygen at 2.5 atmospheres
absolute (which is 1.5 atmospheric pressure in addition to
normal atmospheric pressure) for 80 min, including 10 min
for compression and 10 min for decompression. The first HBO
therapy session was performed within 2 h of retinal ischemia.
Treatments were conducted three times a day for two days,
and then twice a day for seven days
Wistar rats were divided into five groups (n=6/group):
Group 1: control
Group 2: ARI group
Group 3: Memantine group
Group 4: Hyperbaric oxygen (HBO) treatment group
Group 5: Brimonidine group.
1. Control group: Right eyes were cannulated with
a 30-gauge needle and removed without causing any
intraocular pressure change.
2. ARI group: Acute retinal ischemia model but
without treatment.
3. Memantine group: Animals were given unique
dose of intravenous 25 mg/kg Memantine (Ebixa®,
Lundbeck, Merz & Co., Frankfurt, Main, Germany)
by tail vein route in 1 h after inducing acute retinal
ischemia.
4. HBO  group:  2  h  following  the  acute  retinal
ischemia HBO treatment was applied for nine days
at the Department of Underwater and Hyperbaric
Medicine Istanbul Faculty of Medicine.
5. Brimonidine group: 0.15% brimonidine tartrate
eye  drops  (Alphagan,  Allergan,  Inc.  Irvine,
California) treatment was applied twice a day for
seven days before acute retinal ischemia.
Molecular Vision 2011; 17:1024-1033 <http://www.molvis.org/molvis/v17/a115> © 2011 Molecular Vision
1025Twenty-one days after establishing ischemia- reperfusion, the
right  eyes  of  all  rats  were  enucleated  after  cardiac
gluteraldehid  perfusion  method,  and  then  submitted  to
histological evaluation [24,25].
Sacrifice and cardiac perfusion tissue processing: Rats were
deeply anesthetized with ketamine hydrochloride (100 mg/kg)
and chlorpromazine (25 mg/kg) and intracardially perfused
with 2.5% gluteraldehyde in cacodylate buffer solution (0.1
M  cacodylic  acid  sodium  salt,  pH  7.4).  The  eyes  were
enucleated and immersed in 10% neutral formaldehyde in 0.1
M  phosphate  buffer  (pH  7.4)  for  postfixation.  Paraffin-
embedded sections of 20 μm thickness were prepared from
the embedded eye tissue.
Stereological analysis: The optical fractionator method was
used to estimate the total number of RGCs. All cells were
counted  by  the  same  person.  In  the  optical  fractionator
technique,  the  optical  dissector  is  combined  with  the
fractionator sampling scheme [26,27].
Equipment: For quantification, the Stereo Investigator version
7.5 (MicroBrightField, Colchester, VT) was used on a PC
system connected to a Leica DM 4000 microscope (Leica,
Weltzlar,Germany). A motorized automatic stage was used to
control movement in the x,y plane via a connected joystick.
Movement in the z-axis was generated manually with the
focus button on the microscope and the distance was measured
using  a  Heidenhain  electronic  microcator  (Heidenhain,
Traunreut, Germany).
Delineation of the region of Interest and cell counting: After
the section was placed in the microscope, the circumference
of the specimen was delineated using a 4× objective lens. The
counting  was  performed  using  a  63×  Plan  Apo  objective
(NA=1.40).
Sampling: An unbiased estimation of the total number of
ganglion cells was obtained from the eye globe by choosing
every  10th  section  according  to  the  systematic  random
sampling procedure. A sampling area of 900/40,000 µm2 was
found  to  be  optimal  for  this  study.  Dissector  height  was
16 μm, and a 2 μm zone at the uppermost part of the section
was excluded from the analysis at every step as the upper
guard zone. Thus, a thickness sampling fraction of 16 μm/t
was used, where it represents the mean section thickness.
Estimate of total cell number: The total number of cells (N)
in one eye retina was estimated as outlined by West et al.
[26,27] using the equation **n=ΣQ- × 1/tsf ×1/asf ×1/ssf [1],
where ΣQ- represents the total number of RGCs counted in all
optically sampled fields of the retina; ssf is section sampling
fraction (1/10); asf is the area sampling fraction (900/40,000);
and tsf is the thickness sampling fraction (defined by dissector
height  [16  μm])  divided  by  the  estimated  mean  section
thickness.
Immunohistochemical processing: Serial sections of 20 μm
thicknesses of paraffin-embedded blocks were inspected, and
medium  sections  were  selected  for  immunohistochemical
procedure. Thirty eye sections stained with an in situ cell death
detection  kit,  POD  (Roche  Diagnostics;  Mannheim,
Germany) were used for semiquantitative analyses.
The staining procedure was performed according to the
manufacturer’s instructions. Eye sections were deparaffinized
and dehydrated. After rinsing in phosphate buffer saline (PBS;
0.1 mM, pH 7.2), the sections were pretreated. For detergent,
Triton X-100 (Acros Organics; Geel, Belgium) was employed
at 0.1% (v/v) in 0.1% (w/v) sodium citrate (Merck; Darmstadt,
Germany) for 2 min on ice, followed by washing of the slides
twice in PBS at room temperature (RT). We employed an A
Bosch HMT 812C domestic oven operating at a frequency of
2.45 GHz with five power level settings (0–900 W). The best
results were obtained with a setting of 4 (600 W). After placing
the slides in a plastic jar containing 200 ml of 0.01 M citrate
buffer (pH 6), the samples were irradiated them for 45 s, which
resulted in an increase in the temperature from RT to 86 °C.
At the end of irradiation, an extra 80 ml of distilled water at
RT was added to the jar to cool the solution, and the slides
were then quickly immersed in PBS at RT (rapid cooling).
Background was diminished by preincubating samples with
2%  BSA,  10%  normal  goat  serum  (Sigma-Aldrich,
Taufkirchen, Germany), and 0.03% Triton X-100 in double-
distillated water for 30 min at RT. Sections were then treated
with the in situ cell death detection kit, POD, and incubated
for 60 min at 37 °C in a humidified atmosphere in the dark.
Subsequently, the slides were rinsed in PBS three times for 5
min each time. They were then treated for 1 h at RT with a
peroxidase-labeled  antidigoxigenin  sheep  Fab  fragment
(Roche  Diagnostics;  Mannheim,  Germany),  followed  by
washing.  Then,  0.05%  3–3′-diaminobenzidine
tetrahydrochloride  chromogen  concentrate  and
diaminobenzidine  substrate  buffer  (SkyTek,  UT)  mixture
were used for color reaction. Slides were counterstained with
Mayer’s hematoxylin.
Counting: In each sampling frame, the apoptotic, normal, and
necrotic cells were marked using three different markers.
Statistical analysis: All data are expressed as means±standard
error  of  mean  (SEM).  Parametric  test  assumptions  were
available for total RGC number and apoptotic index of the
RGC layer (RGCL) of the eye. They were analyzed by one-
way ANOVA, and then multiple comparisons between pairs
of groups were performed according to Tukey’s test. SPSS
version 16.0 system for personal computer (SPSS, Chicago,
IL)  was  used,  and  p-value  <0.05  was  considered  to  be
statistically significant.
RESULTS
The histomorphometry of the ischemic retina was observed
for retinal damage 21 days after ischemia. Severe damage due
to high intraocular pressure–induced ischemia was observed
in  the  RGCL,  with  approximately  52%  live  cells
(125.137±7.184 cells remained, n=6). Cell numbers in the
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1026normal retina were 239.926±8.599 in the ganglion cell layer
(GCL; n=6, p<0.001). Cell numbers in the MEM group were
215.89±8.36; in the HBO group 208.69±2.05; and in the BRI
group 172.27±8.16. Morphometric analysis showed that the
percentage of surviving RGCs was 86.9%, 89.9%, and 71.7%
compared  to  postischemic  retinas  treated  with  HBO,
memantine,  and  brimonidine  (p<0.001  in  all  treatment
methods). Considering RGC counts, there was no statistically
significant difference between the control group and the MEM
group  (p>0.05),  but  there  was  a  statistically  significant
difference between the control and the HBO (p<0.05) and BRI
groups (p<0.001). There was also a statistically significant
difference between the ARI group and MEM group (p<0.001),
HBO group (p<0.001), and BRI group (p<0.01; Figure 1 and
Table 1).
Figure 1. Morphometric analysis of the rat retina shows surviving cells in ganglion cell layer. Left side panel of graph compares to control
and treatment groups. There were significant decreases for the surviving cell number of ganglion cell layer in hyperbaric oxygen (HBO)
therapy, and brimonidine (BRI) treatment groups. *** p<0.001, *p<0.05. The data showed no significant differences (p<0.05) between the
memantine (MEM) treated and control groups. Right side panel of graph compares to the acute retinal ischemia (ARI) and treatment groups.
There were significant decreases for the surviving cell number of ganglion cell layer in all treated groups. **p<0.01 and ***p<0.001.
TABLE 1. GENERAL OPTICAL DISSECTOR.






Mean total retinal ggl
cell count ±SEM
239,926±8,599 125,137±7,184 215,894±8,361 208,687±2,053 172,265±8,158
Dissector particle
number
443 231 358 397 326
Section thickness (µm) 19.5 19.5 21.7 19.0 19.3
Number of sampled
sections
26.3 23.5 24.3 31.3 26.8
CE 0.05 0.07 0.05 0.05 0.06
CV 0.09 0.14 0.09 0.02 0.12
        Mean total ganglion cell count ±SEM, mean dissector number, section thickness, number of sampled sections, coefficient of
        error, and coefficient of variation of stereological analysis between subjected to ischemia/reperfusion and treatment groups in
        the rodents.
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1027Terminal  Uridine  Nick  3′  End  Labeling  (TUNEL)-
positive stained cells were observed only in the GCL. At three
weeks postischemia in the ARI group (n=6), the number of
TUNEL-positive  cells  had  increased  significantly  in  each
section (57.71±0.58% in the ARI group versus 1.1±0.85% in
control; p<0.001; n=6). In the HBO therapy group (15.6 ±
0.58%; p<0.001; n=6), MEM treatment group (23.6±1.73%;
p<0.001;  n=6),  and  BRI  treatment  group  (29.37±2.55%;
p<0.001; n=6), the percentage of TUNEL-positive cells in the
RGCL in each section was significantly reduced compared to
the ischemic retina. Considering the apoptotic index count,
there was a statistically significant difference between the
control group and the MEM group (p<0.001), HBO group
(p<0.001),  and  BRI  group  (p<0.001).  There  was  also  a
statistically significant difference between the ARI group and
the  MEM  group  (p<0.001),  but  there  was  no  statistically
significant difference between the ARI group and HBO group
(p>0.05) or BRI group (p>0.05; Figure 2, Figure 3, Figure 4,
and Table 2).
DISCUSSION
The present study shows that memantine and HBO therapy
were  effective  in  reducing  the  damage  induced  by  acute
ischemia reperfusion in the rat retina. Brimonidine was found
to be the least effective therapy. Our study suggests that these
treatments had beneficial effects due to neuroprotection, and
may therefore be applied in clinical practice.
In  this  study,  the  ischemia  reperfusion  model  was
obtained through an acute increase of intraocular pressure
because in this type of research, this ischemia reperfusion
model is widely preferred. Moreover, central retinal artery
occlusion  may  be  directly  observed  by  ocular  fundus
examination in this approach. The validity of our ischemia
reperfusion model was proved by comparing the mean RGC
count and apoptotic index between the ARI group and control
group; a statistically significant difference was found between
these groups. This result showed that the ARI model was
effective.  A  bolus  intravenous  injection  of  memantine  of
25 mg/kg was found to be lethal on rabbits. Smaller doses such
as  1–10  mg/kg  had  neither  side  effects  nor  effectiveness
[28]. Philip et al. [29] applied 20 mg/kg bolus intravenous
injections  of  memantine  on  rats  and  no  lethal  effect  was
evident. In our pilot study on rats, we showed that a 25 mg/kg
bolus intravenous injection of memantine was not lethal. We
can  conclude  that  rabbits  are  more  sensitive  than  rats.
Therefore, we suggest that further clinical studies are needed
to investigate doses of intravenous injection of memantine
that are effective and not lethal.
CRAO is a typical example of ARI. Since 1859, Van
Graefe first described central retinal artery occlusion (CRAO)
as an embolic event to the central retinal artery in a patient
with endocarditis [10-12], classical and complex treatments
have  not  yet  yielded  the  success  expected.  The  classical
proposed  HBO  therapy  has  the  limitation  that  it  must  be
applied  soon  after  the  occurrence  of  the  ischemia.  The
generally  admitted  period  in  which  the  therapy  will  be
effective is 6 h, but in humans the duration of this critical
period  is  impossible  to  determine.  It  is  generally
acknowledged that an accurate and rapid therapy must be
applied within 24 h. Therefore, a practical, urgent treatment
is needed and our study targeted the goal of identifying this
treatment [11-14].
Figure 2. The effect of raised intraocular pressure-induced ischemia for 60 min and reperfusion for 21 days on the percentage of apoptotic
(TUNEL positive) cell in rat retina. There is a significant decrease of apoptotic (TUNEL positive) cell (+) cells (***p<0.001) in the control
retina compared to treatment groups (MEM, HBO, and BRI) in the left-side graphs. However, there is a significant increase of apoptotic cells
(***p<0.001) in retinas subjected to ischemia/reperfusion compared to treatment groups in the right-side graphs. Error bars are ±SEM, where
n=6.
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1028Figure 3. Photomicrographs showing the ganglion cell (black arrow) of the retina from the mature rat. A: control, B: ARI, C: memantine,
D: HBO therapy, and E: brimonidine. Hematoxylin and eosin stain; Bar 50 µm.
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1029Figure 4. Photomicrographs showing the apoptotic ganglion cell (black arrow) of the retina from the mature rat. A; control B: ARI, C:
memantine, D: HBO therapy, and E: brimonidine. TUNEL+ diaminobenzidine, counter stain hematoxylin; Bar 50 µm.
Molecular Vision 2011; 17:1024-1033 <http://www.molvis.org/molvis/v17/a115> © 2011 Molecular Vision
1030Neuroprotection has been a matter of debate for years,
since the introduction of experimental ischemia and glaucoma
models to the ophthalmology literature. RGCs are a major
target for both the quantification of the ischemic damage and
evaluation of the therapeutic potential of the agent that is used.
It is well established that the death of RGCs secondary to
ischemia has been known to occur via the process called
apoptosis [30]. An increasing amount of evidence indicates
that  drugs  that  show  antiapoptotic  activity  may  decrease
neuronal death, a major aim of neuroprotective therapy [31,
32].
As  a  result  of  these  considerations,  in  our  study,  the
percentage of cells undergoing apoptosis was accepted as a
main outcome measure, together with the total number of
RGCs. To have neuroprotective efficiency, a drug must have
properties like good vitreous diffusion, durability, and high
concentration value in targeted tissues. Furthermore, it must
have correspondent receptor binding sites, presumably on the
optic nerve or the retina.
The neuroprotective effects of memantine and topical
bunazosin were investigated in an optic nerve ischemia model
induced  by  the  delivery  of  endothelin-1  (ET–1)  [33,34].
Memantine,  an  NMDA  antagonist,  was  shown  to  be
efficacious in terms of the topographic parameters of the optic
nerve (cup area, cup depth, and rim volume); in addition, it
was found to be neuroprotective in a rabbit model of optic
nerve ischemia [33]. Memantine is currently being used in
Europe for the treatment of Parkinson disease and spasticity,
and it was recently approved in Europe for the treatment of
Alzheimer disease and vascular dementia [18].
The  neuroprotective  effect  of  memantine  has  been
demonstrated in many studies, especially in terms of acute
brain ischemia [34,35]. In ophthalmology, however, contrary
to our ARI model, these treatments were essentially applied
to chronic glaucoma models in experimental studies. To our
knowledge, only a few animal studies about neuroprotective
treatments in ARI have been performed [36-38]. The aim of
one  of  the  studies  was  to  quantify  vitreous  amino  acid
concentrations in pressure-induced retinal ischemia, and to
evaluate  the  neuroprotective  effect  of  memantine
administered before and at two time intervals after ischemia
[38]. They indicated that memantine reduced ganglion cell
loss when given systemically before or within 30 min of
retinal ischemia.
Lagrèze et al. [39] induced acute ischemia reperfusion
injury  in  rats  and  compared  the  efficacy  of  cerestat,
memantine, and riluzole. As a result, they argued that these
drugs have a neuroprotective effect, reducing the excitotoxic
damage  of  retinal  neurons.  Wolde  Mussie  et  al.  [38]
investigated  the  neuroprotective  effect  of  Memantine,  an
NMDA receptor channel blocker, in two RGC injury models
in rats. They found that there was an approximately 80%
reduction in RGC number two weeks after the partial optic
nerve injury. In that study, memantine (5 mg/kg) caused a
twofold increase in compound action potential amplitude and
a 1.7 fold increase in the survival of RGCs.
In terms of apoptotic index and RGC count, there was no
statistically significant difference in our study between the
control group and the MEM group (p>0.05). These results are
consistent with those of other studies [23,36-39]. However, a
statistically significant difference was found between the ARI
group and MEM group. Therefore, we assume that a single
bolus dose of memantine may have a neuroprotective effect
in ARI.
In view of the apoptotic index, contrary to the statistically
significant  difference  found  between  the  ARI  and  HBO
groups,  there  was  no  statistically  significant  difference
between the ARI and MEM groups. We think that these results
may  be  due  to  cell  death  originating  from  a  necrotic
mechanism more than from apoptosis. In addition, our study
showed that memantine has a neuroprotective effect after
ARI.
The  European  Committee  of  Hyperbaric  Medicine
determined the indications of HBO therapy. The treatment
priority of acute ocular ischemic pathologies is classified as
level  C,  meaning  optional.  However,  in  ophthalmological
practice, HBO is the first-choice therapy in ARI. In HBO
treatment studies on clinical conditions implying ARI, the
clinical neuroprotective effect of HBO has been discussed
[40,41]. Nevertheless, the efficacy of this method has not been
proven immunohistochemically by experimental studies. The
major parameters of the studies were visual prognosis and the
time lag from the onset of symptoms to the beginning of
hyperbaric oxygenation treatment, as well as the time lag until
the beginning of retinal reperfusion. Beiran et al. [3] and
Weinberger et al. [4] concluded that HBO therapy appears to
have a beneficial effect on visual outcome in patients with
CRAO.
Our study showed the neuroprotective effects of HBO by
immunohistochemically  evaluating  RGC  counts  and
apoptotic index in an ARI model. The neuroprotective effects
of HBO were compared to those of memantine and were found
TABLE 2. APOPTOTIC INDEX OF THE EXPERIMENTAL GROUPS.






Mean apoptotic index percentage
(TUNEL [+] cells/total cells) ±SEM
1.1±0.35 57.71±0.58 23.57±1.73 15.63±2.08 29.37±2.55
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1031to be similar. In view of the results of our study, we think that
HBO therapy seem to be more effective. When comparing the
efficacy of memantine and HBO treatments using the same
parameters, they show equivalent therapeutic value. We think
that the difference in apoptotic index noted between these two
groups  may  come  from  an  unexplained  mechanism  of
apoptosis.
Brimonidine  tartrate,  an  α2-receptor  agonist,  is  an
accepted  treatment  modality  for  the  medical  treatment  of
glaucoma.  The  α2-receptor  agonists  have  been  shown  to
protect  RGCs  in  experimental  models  of  optic  nerve
degeneration [42], chronic ocular hypertension [43], transient
ischemia [44], and photoreceptor degeneration [45]. Aktas et
al. [46] have shown the neuroprotective effect of topically
applied BRI in a rabbit model of endothelin-1-induced optic
nerve  ischemia.  As  a  topical  agent,  brimonidine  was
considered to have neuroprotective effects if it could penetrate
into the vitreous, maintain its topical application for a given
period of time, and have receptors on its target tissues, e.g.,
the retina and the optic nerve [47].
Based on knowledge about brimonidine receptors and
pharmacological  concentrations  of  the  drug  in  the  retina,
researchers have suggested that the neuroprotective effect of
brimonidine may be mediated by vascular modulation or by
the upregulation of brain-derived neurotrophic factor in the
RGCs  [48].  Accordingly,  brimonidine  treatment  was
associated with a significant prevention of RGC injury [43].
The effects of brimonidine were reported to include a dose-
dependent increase in RGC survival and functioning in a
partial crush injury model [20]. In this study, we found a
statistically significant difference between the BRI and ARI
groups when considering RGC count and apoptotic index.
When comparing the HBO and MEM groups with the BRI
group, there was no statistically significant difference. In view
of these data, further studies need to focus on the modality of
the application of brimonidine, along with its duration and
doses in ARI treatment.
In  conclusion,  a  single  bolus  dose  of  intravenous
memantine  and  HBO  therapy  were  found  to  be  highly
effective  in  the  treatment  of  ARI;  however,  the  topical
application of brimonidine was also found to be effective in
terms of prophylactic treatment. In this manner, brimonidine
seems to be a good choice for preventive therapy for patient
at high risk of developing CRAO. Our study shows that when
HBO therapy is not immediately available, or some time is
needed, as occurs in most cases, memantine and brimonidine
seem to be practical and valuable therapeutic and prophylactic
agents in acute ischemia. Further and more detailed clinical
studies  of  these  two  treatments  are  needed  that  aim  at
determining modes of application, doses, and maximum time
elapsed after the ischemia period.
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